Puma Biotechnology
Puma Biotechnology: Cheap But Quite Risky (NASDAQ:PBYI) | Seeking Alpha
EX-99.1
Puma Biotechnology Inc Company Profile - GlobalData
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Marcus Morreale - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (PBYI) BCG Matrix Analysis
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotechnology begins Phase II trial of lung cancer drug
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. (PBYI): history, ownership, mission, how it works & makes money
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates | Nasdaq
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now | Nasdaq
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotech Surges, Defying Yellen
Jon Mead - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
pbyi-10k_20171231.htm
